Literature DB >> 21856939

HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells.

Karuppiah Muthumani1, Devon J Shedlock, Daniel K Choo, Paolo Fagone, Omkar U Kawalekar, Jonathan Goodman, Chaoran B Bian, Aarti A Ramanathan, Parikh Atman, Pablo Tebas, Michael A Chattergoon, Andrew Y Choo, David B Weiner.   

Abstract

Recent evidence demonstrates that HIV-1 infection leads to the attenuation of cellular immune responses, which has been correlated with the increased expression of programmed death (PD)-1 on virus-specific CD8(+) T cells. PD-1 is induced upon T cell activation, and its prolonged expression facilitates CD8(+) T cell inhibitory signals when bound to its B7 family ligands, PD-ligand (L)1/2, which are expressed on APCs. Importantly, early reports demonstrated that blockade of the PD-1/PD-L interaction by Abs may help to counter the development of immune exhaustion driven by HIV viral persistence. To better understand the regulation of the PD-1 pathway during HIV infection, we examined the ability of the virus to induce PD-L expression on macrophages and dendritic cells. We found a direct relationship between the infection of APCs and the expression of PD-L1 in which virus-mediated upregulation induced a state of nonresponsiveness in uninfected HIV-specific T cells. Furthermore, this exhaustion phenotype was revitalized by the blockade of PD-L1, after which T cells regained their capacity for proliferation and the secretion of proinflammatory cytokines IFN-γ, IL-2, and IL-12 upon restimulation. In addition, we identify a critical role for the PI3K/serine-threonine kinase signaling pathway in PD-L1 upregulation of APCs by HIV, because inhibition of these intracellular signal transducer enzymes significantly reduced PD-L1 induction by infection. These data identify a novel mechanism by which HIV exploits the immunosuppressive PD-1 pathway and suggest a new role for virus-infected cells in the local corruption of immune responses required for viral suppression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21856939      PMCID: PMC3197696          DOI: 10.4049/jimmunol.1100594

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands.

Authors:  Angela Meier; Aranya Bagchi; Harlyn K Sidhu; Galit Alter; Todd J Suscovich; Daniel G Kavanagh; Hendrik Streeck; Mark A Brockman; Sylvie LeGall; Judith Hellman; Marcus Altfeld
Journal:  AIDS       Date:  2008-03-12       Impact factor: 4.177

Review 2.  Toward an AIDS vaccine.

Authors:  Bruce D Walker; Dennis R Burton
Journal:  Science       Date:  2008-05-09       Impact factor: 47.728

3.  NFATc1 regulates PD-1 expression upon T cell activation.

Authors:  Kenneth J Oestreich; Hyesuk Yoon; Rafi Ahmed; Jeremy M Boss
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

4.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

Authors:  E John Wherry; Sang-Jun Ha; Susan M Kaech; W Nicholas Haining; Surojit Sarkar; Vandana Kalia; Shruti Subramaniam; Joseph N Blattman; Daniel L Barber; Rafi Ahmed
Journal:  Immunity       Date:  2007-10-18       Impact factor: 31.745

Review 5.  HIV-1 viral genes and mitochondrial apoptosis.

Authors:  Devon J Shedlock; Daniel Hwang; Andy Y Choo; Christopher W Chung; Karuppiah Muthumani; David B Weiner
Journal:  Apoptosis       Date:  2008-07-12       Impact factor: 4.677

6.  Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus.

Authors:  Karuppiah Muthumani; Katthikbabu M Lankaraman; Dominick J Laddy; Senthil G Sundaram; Christopher W Chung; Eric Sako; Ling Wu; Amir Khan; Niranjan Sardesai; Joseph J Kim; Paluru Vijayachari; David B Weiner
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

Review 7.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

8.  Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction.

Authors:  Lucy Golden-Mason; Brent Palmer; Jared Klarquist; John A Mengshol; Nicole Castelblanco; Hugo R Rosen
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

9.  Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction.

Authors:  Michelle D'Souza; Andrew P Fontenot; Doug G Mack; Catherine Lozupone; Stephanie Dillon; Amie Meditz; Cara C Wilson; Elizabeth Connick; Brent E Palmer
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

10.  PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes.

Authors:  Adriano Boasso; Andrew W Hardy; Alan L Landay; Jeffrey L Martinson; Stephanie A Anderson; Matthew J Dolan; Mario Clerici; Gene M Shearer
Journal:  Clin Immunol       Date:  2008-07-22       Impact factor: 3.969

View more
  18 in total

1.  Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.

Authors:  Kar Muthumani; Seleeke Flingai; Megan Wise; Colleen Tingey; Kenneth E Ugen; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2013-09-17       Impact factor: 3.452

2.  Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines.

Authors:  Lingyun Yang; Feng Huang; Jiandong Mei; Xun Wang; Qiuyang Zhang; Hongjing Wang; Mingrong Xi; Zongbing You
Journal:  Int J Gynecol Cancer       Date:  2017-02       Impact factor: 3.437

Review 3.  Role of PD-1 in HIV pathogenesis and as target for therapy.

Authors:  Filippos Porichis; Daniel E Kaufmann
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

Review 4.  Regulation and Function of the PD-L1 Checkpoint.

Authors:  Chong Sun; Riccardo Mezzadra; Ton N Schumacher
Journal:  Immunity       Date:  2018-03-20       Impact factor: 31.745

5.  Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.

Authors:  Xun Wang; Lingyun Yang; Feng Huang; Qiuyang Zhang; Sen Liu; Lin Ma; Zongbing You
Journal:  Immunol Lett       Date:  2017-02-14       Impact factor: 3.685

Review 6.  Generation, secretion and degradation of cancer immunotherapy target PD-L1.

Authors:  Dan-Dan Shen; Ya-Ping Bi; Jing-Ru Pang; Li-Juan Zhao; Long-Fei Zhao; Ya Gao; Bo Wang; Hui-Min Liu; Ying Liu; Ning Wang; Yi-Chao Zheng; Hong-Min Liu
Journal:  Cell Mol Life Sci       Date:  2022-07-11       Impact factor: 9.207

Review 7.  Manipulation of costimulatory molecules by intracellular pathogens: veni, vidi, vici!!

Authors:  Nargis Khan; Uthaman Gowthaman; Susanta Pahari; Javed N Agrewala
Journal:  PLoS Pathog       Date:  2012-06-14       Impact factor: 6.823

8.  HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo.

Authors:  Kar Muthumani; Megan C Wise; Kate E Broderick; Natalie Hutnick; Jonathan Goodman; Seleeke Flingai; Jian Yan; Chaoran B Bian; Janess Mendoza; Colleen Tingey; Christine Wilson; Krzysztof Wojtak; Niranjan Y Sardesai; David B Weiner
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 9.  Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options.

Authors:  Vijayakumar Velu; Ravi Dyavar Shetty; Marie Larsson; Esaki M Shankar
Journal:  Retrovirology       Date:  2015-02-08       Impact factor: 4.602

10.  Co-Administration of Molecular Adjuvants Expressing NF-Kappa B Subunit p65/RelA or Type-1 Transactivator T-bet Enhance Antigen Specific DNA Vaccine-Induced Immunity.

Authors:  Devon J Shedlock; Colleen Tingey; Lavanya Mahadevan; Natalie Hutnick; Emma L Reuschel; Sagar Kudchodkar; Seleeke Flingai; Jenny Yan; Joseph J Kim; Kenneth E Ugen; David B Weiner; Kar Muthumani
Journal:  Vaccines (Basel)       Date:  2014-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.